Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07104812

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Sponsor: Mayo Clinic

Conditions Autonomous Cortisol Secretion (ACS) Mild Autonomous Cortisol Secretion

Updated 3 times since 2025 Last updated: Feb 8, 2026 Started: Jan 14, 2026 Primary completion: Jan 31, 2027 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07104812, this PHASE2 trial focuses on Autonomous Cortisol Secretion (ACS) and Mild Autonomous Cortisol Secretion and remains actively recruiting participants. Sponsored by Mayo Clinic, it has been updated 3 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2
Sep 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic
RECORDATI GROUP

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States